Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom-Reference-Cited by-同舟云学术

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom

Published:2023-01-11 Issue:3 Volume:40 Page:1282-1291
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Sandhu Hera,Xu Weiwei,Olivieri Anamaria-Vera,Lübker Christopher^ORCID,Smith Inger,Antavalis Vasileios

Funder

Novo Nordisk

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02423-8.pdf

Reference30 articles.

1. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.

2. Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: a chronic relapsing progressive disease process A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.

3. National Health Service. Health Survey for England 2019: overweight and obesity in adults and children; 2020. https://files.digital.nhs.uk/9D/4195D5/HSE19-Overweight-obesity-rep.pdf.

4. Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European countries and in the USA. Obes Facts. 2020;13(5):514–27.

5. Public Health England. Health matters: obesity and the food environment; 2017. https://www.gov.uk/government/publications/health-matters-obesity-and-the-food-environment/health-matters-obesity-and-the-food-environment--2. Accessed 19 Oct 2022.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review;European Journal of Clinical Pharmacology;2024-09-10

2. Obesity and cardiovascular disease: an ESC clinical consensus statement;European Journal of Preventive Cardiology;2024-08-30

3. Obesity and cardiovascular disease: an ESC clinical consensus statement;European Heart Journal;2024-08-30

4. Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care;Pragmatic and Observational Research;2024-08

5. Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal;Diabetology & Metabolic Syndrome;2024-04-30